The potential protective role of hepatitis B virus infection in pristane-induced lupus in mice
Abstract
Objective
The objective of this study was to investigate whether hepatitis B virus (HBV) infection plays a role in the regulation of autoimmunity for systemic lupus erythematosus (SLE).
Method
A total of 21 female BALB/c mice and 21 female HBV transgenic BALB/c mice aged two months were randomly divided into four groups: BALB/c mice, HBVTg mice, pristane-injected BALB/c mice, and pristane-injected HBVTg mice. BALB/c mice and HBVTg mice were given an intraperitoneal injection of 0.5 ml normal saline, and the mice in the other two groups were given an intraperitoneal injection of 0.5 ml pristane. ANA and anti-dsDNA levels in serum were detected by indirect immunofluorescence. Interleukin 2 (IL-2), IL-4, IL-6, IL-17, and TNF-α were measured by Luminex technology. The serum BAFF level was measured using an Elisa kit. Twenty-four weeks after pristane administration, kidneys were removed, dissected, and stained with hematoxylin and eosin and periodic-acid Schiff.
Result
At six months after injecting, the ANA titers in pristane-injected HBVTg mice were significantly lower than pristane-injected BALB/c mice. IL-17, TNF-α, and BAFF levels were significantly higher in pristane-injected BALB/c mice than BALB/c mice and pristane-injected HBVTg mice. IL-2, IL-4, and IL-6 levels were much higher in pristane-injected HBVTg mice than pristane-injected BALB/c mice. In pristane-injected HBVTg mice and HBVTg mice, fewer glomerulonephritis changes were found in the kidneys.
Conclusions
Our results showed that the incidence of SLE was much lower in HBVTg mice, and that HBV infection helped the SLE mice survive high levels of inflammatory cytokines and severe renal damage. All these findings demonstrated the protective role of HBV in SLE patients via the immunoregulatory networks of the cytokines.
Get full access to this article
View all access and purchase options for this article.
References
1. Azevedo PC, Murphy G, Isenberg DA. Pathology of systemic lupus erythematosus: the challenges ahead. Methods Mol Biol 2014; 1134: 1–16.
2. Anolik JH. B cell biology: implications for treatment of systemic lupus erythematosus. Lupus 2013; 22: 342–349.
3. Tenbrock K. Pathogenesis and new therapeutic approaches for systemic lupus erythematosus. Z Rheumatol 2014; 73: 890–896.
4. Biermann MH, Veissi S, Maueroder C, et al. The role of dead cell clearance in the etiology and pathogenesis of systemic lupus erythematosus: dendritic cells as potential targets. Expert Rev Clin Immunol 2014; 10: 1151–1164.
5. Draborg AH, Duus K, Houen G. Epstein–Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012; 4: 3701–3730.
6. Hepburn AL, Davies KA. Infection and SLE. Ann Rheum Dis 2002; 61: 668–669.
7. Renshaw SA, Parmar JS, Singleton V, et al. Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 2003; 170: 1027–1033.
8. Ram M, Anaya JM, Barzilai O, et al. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev 2008; 7: 621–625.
9. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infect Dis 2002; 2: 43–50.
10. Lau GK. Hepatitis B infection in China. Clin Liver Dis 2001; 5: 361–379.
11. Nie H, Wang YY, Wang Y, Shi J, Chen WX. Correlative analysis of different HBV genotypes and autoantibodies in hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2012; 20: 448–452.
12. Mac-Moune Lai F, Lai KN, Lee JC, Hom BL. Hepatitis B virus-related glomerulopathy in patients with systemic lupus erythematosus. Am J Clin Pathol 1987; 88: 412–420.
13. Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfá E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007; 16: 350–354.
14. Watanabe R, Ishii T, Kobayashi H, et al. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in Tohoku area: a retrospective multicenter survey. Tohoku J Exp Med 2014; 233: 129–133.
15. Zhao J, Qiu M, Li M, Lu C, Gu J. Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China. Rheumatol Int 2010; 30: 1565–1570.
16. Li X, Liu X, Tian L, Chen Y. Cytokine-mediated immunopathogenesis of hepatitis B virus infections. Clin Rev Allergy Immunol 2016; 50: 41–54.
17. Nozaki Y, Yamagata T, Yoo BS, et al. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice. Clin Exp Immunol 2005; 139: 74–83.
18. Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity – friends or foes? Trends Immunol 2009; 30: 409–414.
19. Ochoa-Reparaz J, Kasper LH. Gut microbiome and the risk factors in central nervous system autoimmunity. FEBS Lett 2014; 588: 4214–4222.
20. Ruff WE, Vieira SM, Kriegel MA. The role of the gut microbiota in the pathogenesis of antiphospholipid syndrome. Curr Rheumatol Rep 2015; 17: 472–472.
21. Vieira SM, Pagovich OE, Kriegel MA. Diet, microbiota and autoimmune diseases. Lupus 2014; 23: 518–526.
22. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol 2015; 37: 47–55.
23. Taneja V. Arthritis susceptibility and the gut microbiome. FEBS Lett 2014; 588: 4244–4249.
24. Agmon-Levin N, Arango MT, Kivity S, et al. Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model. J Autoimmun 2014; 54: 21–32.
25. Sterner RM, Hartono SP, Grande JP. The pathogenesis of lupus nephritis. J Clin Cell Immunol 2014; 5: 205–205.
26. Arababadi MK, Pourfathollah AA, Jafarzadeh A, et al. The status of humoral immunity in occult HBV infection in south-eastern Iranian patients. Clin Res Hepatol Gastroenterol 2011; 35: 309–314.
27. Mosca M, Tani C, Filice ME, et al. TNF-alpha inhibitors in systemic lupus erythematosus. A case report and a systematic literature review. Mod Rheumatol 2015; 25: 642–645.
28. Zhu LJ, Yang X, Yu XQ. Anti-TNF-alpha therapies in systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010: 465898–465898.
29. Zhu L, Yang X, Chen W, et al. Decreased expressions of the TNF-alpha signaling adapters in peripheral blood mononuclear cells (PBMCs) are correlated with disease activity in patients with systemic lupus erythematosus. Clin Rheumatol 2007; 26: 1481–1489.
30. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014; 10: 365–373.
31. Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 2013; 65: 2672–2679.
32. Zayed RA, Sheba HF, Abo Elazaem MA, et al. B-cell activating factor promoter polymorphisms in egyptian patients with systemic lupus erythematosus. Ann Clin Lab Sci 2013; 43: 289–294.
33. Kasprzak A, Zabel M, Wysocki J, Seidel J, Surdyk-Zasada J, Filipiak B. Expression of mRNA for cytokines (TNF-alpha and IL-1alpha) in human cytomegalovirus (HCMV) and hepatitis B virus (HBV) infections. Folia Histochem Cytobiol 2002; 40: 63–68.
34. Toubi E, Gordon S, Kessel A, et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun 2006; 27: 134–139.
35. Huard B, Arlettaz L, Ambrose C, et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol 2004; 16: 467–475.
36. Miyake K, Akahoshi M, Nakashima H. Th subset balance in lupus nephritis. J Biomed Biotechnol 2011; 2011: 980286–980286.
37. Miyake K, Sasatomi Y, Nakashima H. Lupus nephritis associated with nephrotic syndrome. Nihon Rinsho Meneki Gakkai Kaishi 2013; 36: 129–133.
38. Penna A, Del Prete G, Cavalli A, et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997; 25: 1022–1027.
39. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821–852.
40. Jacob N, Yang H, Pricop L, et al. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009; 182: 2532–2541.
41. Kurasawa K, Hirose K, Sano H, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43: 2455–2463.
42. Ge J, Wang K, Meng QH, Qi ZX, Meng FL, Fan YC. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol 2010; 30: 60–67.
43. Ye Y, Xie X, Yu J, et al. Involvement of Th17 and Th1 effector responses in patients with Hepatitis B. J Clin Immunol 2010; 30: 546–555.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: July 11, 2016
Issue published: October 2016
Keywords
PubMed: 27125291
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 157
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 9 view articles Opens in new tab
Crossref: 10
-
Systemic lupus erythematosus is associated with lower risk of hepatiti...
-
B cell-activating factor (BAFF) from dendritic cells, monocytes and ne...
-
Association between nucleos(t)ide analogue therapy for hepatitis B and...
-
Infections in early systemic lupus erythematosus pathogenesis
-
Association of HLA-G + 3142G > C gene polymorphism and toll-like recep...
-
Infections: a double-edge sword in autoimmunity
-
Systemic Lupus Erythematosus
-
Prevalence of hepatitis B virus and hepatitis C virus infection in pat...
-
Association of genetic variation in B-cell activating factor with chro...
-
Chronic hepatitis C viral infection among SLE patients: the significan...
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
